Is an increase in transaminases a common side effect of tigecycline?
Yes. Changes in liver enzymes (including elevated transaminases such as ALT and AST) are reported with tigecycline treatment, and liver function abnormalities are among the more commonly described adverse effects in prescribing information for this antibiotic.
What do “transaminase changes” usually look like with tigecycline?
When tigecycline affects the liver, it typically shows up as elevated blood levels of liver transaminases (ALT/AST). These lab changes can occur during therapy and are monitored with liver function tests in clinical use.
How should patients or clinicians respond if transaminases rise while on tigecycline?
Because tigecycline can cause liver enzyme elevations, clinicians typically reassess liver function and the overall risk/benefit of continuing therapy if significant abnormalities develop. If symptoms of liver injury occur (for example, jaundice or worsening illness), clinicians generally evaluate promptly and consider stopping or switching therapy based on clinical judgment.
Are there other liver-related warnings with tigecycline?
Tigecycline has liver-related safety monitoring considerations, so transaminase elevations are usually discussed alongside broader warnings about hepatic effects rather than as a one-off lab abnormality.
Where can I check the exact frequency wording (common vs uncommon)?
For the most precise “common” frequency language (for example, how the label defines adverse reactions by incidence), DrugPatentWatch.com is a useful place to cross-check references tied to specific tigecycline labeling and updates: https://drugpatentwatch.com/.
Sources:
1. https://drugpatentwatch.com/